Tumour hypoxia is a well-recognised barrier to anti-cancer therapy and represents one of the best validated targets in oncology. Previous attempts to tackle hypoxia have focussed primarily on increasing tumour oxygen supply; however, clinical studies using this approach have yielded only modest clinical benefit, with often significant toxicity and practical limitations. Therefore, there are currently no anti-hypoxia treatments in widespread clinical use. As an emerging alternative strategy, we discuss the relevance of inhibiting tumour oxygen metabolism to alleviate hypoxia and highlight recently initiated clinical trials using this approach.
Journal article
2019-01-01T00:00:00+00:00
92
Cell Hypoxia, Disease Progression, Drug Delivery Systems, Female, Humans, Male, Needs Assessment, Neoplasm Invasiveness, Nimorazole, Oxygen Consumption, Prognosis, Radiotherapy, Randomized Controlled Trials as Topic, Tumor Burden, Tumor Hypoxia